Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units
Copyright © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved..
The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
---|---|
Enthalten in: |
Medicina intensiva - 46(2022), 2 vom: 01. Feb., Seite 81-89 |
Sprache: |
Englisch |
---|
Links: |
---|
Anmerkungen: |
Date Completed 08.02.2022 Date Revised 08.02.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.medine.2021.11.019 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM334399408 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM334399408 | ||
003 | DE-627 | ||
005 | 20231225223627.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.medine.2021.11.019 |2 doi | |
028 | 5 | 2 | |a pubmed24n1114.xml |
035 | |a (DE-627)NLM334399408 | ||
035 | |a (NLM)34903475 | ||
035 | |a (PII)S2173-5727(21)00179-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Vidal-Cortés, P |e verfasserin |4 aut | |
245 | 1 | 0 | |a Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 08.02.2022 | ||
500 | |a Date Revised 08.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved. | ||
520 | |a The COVID-19 pandemic has led to the admission of a high number of patients to the ICU, generally due to severe respiratory failure. Since the appearance of the first cases of SARS-CoV-2 infection, at the end of 2019, in China, a huge number of treatment recommendations for this entity have been published, not always supported by sufficient scientific evidence or with methodological rigor necessary. Thanks to the efforts of different groups of researchers, we currently have the results of clinical trials, and other types of studies, of higher quality. We consider it necessary to create a document that includes recommendations that collect this evidence regarding the diagnosis and treatment of COVID-19, but also aspects that other guidelines have not considered and that we consider essential in the management of critical patients with COVID-19. For this, a drafting committee has been created, made up of members of the SEMICYUC Working Groups more directly related to different specific aspects of the management of these patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a COVID-19 Testing | |
650 | 4 | |a COVID-19 drug treatment | |
650 | 4 | |a Critical care | |
650 | 4 | |a Críticos | |
650 | 4 | |a Intensive Care Units | |
650 | 4 | |a Prueba de COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a Tratamiento farmacológico de la COVID-19 | |
650 | 4 | |a Unidades de Cuidados Intensivos | |
700 | 1 | |a Díaz Santos, E |e verfasserin |4 aut | |
700 | 1 | |a Aguilar Alonso, E |e verfasserin |4 aut | |
700 | 1 | |a Amezaga Menéndez, R |e verfasserin |4 aut | |
700 | 1 | |a Ballesteros, M Á |e verfasserin |4 aut | |
700 | 1 | |a Bodí, M A |e verfasserin |4 aut | |
700 | 1 | |a Bordejé Laguna, M L |e verfasserin |4 aut | |
700 | 1 | |a Garnacho Montero, J |e verfasserin |4 aut | |
700 | 1 | |a García Sánchez, M |e verfasserin |4 aut | |
700 | 1 | |a López Sánchez, M |e verfasserin |4 aut | |
700 | 1 | |a Martín-Loeches, I |e verfasserin |4 aut | |
700 | 1 | |a Ochagavía Calvo, A |e verfasserin |4 aut | |
700 | 1 | |a Ramírez Galleymore, P |e verfasserin |4 aut | |
700 | 1 | |a Alcántara Carmona, S |e verfasserin |4 aut | |
700 | 1 | |a Andaluz Ojeda, D |e verfasserin |4 aut | |
700 | 1 | |a Badallo Arébalo, O |e verfasserin |4 aut | |
700 | 1 | |a Barrasa González, H |e verfasserin |4 aut | |
700 | 1 | |a Borges Sa, M |e verfasserin |4 aut | |
700 | 1 | |a Castellanos-Ortega, Á |e verfasserin |4 aut | |
700 | 1 | |a Estella, Á |e verfasserin |4 aut | |
700 | 1 | |a Ferrer Roca, R |e verfasserin |4 aut | |
700 | 1 | |a Fraile Gutiérrez, V |e verfasserin |4 aut | |
700 | 1 | |a Fuset Cabanes, M |e verfasserin |4 aut | |
700 | 1 | |a Giménez-Esparza Vich, C |e verfasserin |4 aut | |
700 | 1 | |a González Iglesias, C |e verfasserin |4 aut | |
700 | 1 | |a Hernández-Tejedor, A |e verfasserin |4 aut | |
700 | 1 | |a Igeño Cano, J C |e verfasserin |4 aut | |
700 | 1 | |a Iglesias Posadilla, D |e verfasserin |4 aut | |
700 | 1 | |a Jiménez Rivera, J J |e verfasserin |4 aut | |
700 | 1 | |a Llanos Jorge, C |e verfasserin |4 aut | |
700 | 1 | |a Llompart-Pou, J A |e verfasserin |4 aut | |
700 | 1 | |a López Camps, V |e verfasserin |4 aut | |
700 | 1 | |a Lorencio Cárdenas, C |e verfasserin |4 aut | |
700 | 1 | |a Marcos Neira, P |e verfasserin |4 aut | |
700 | 1 | |a Martín Delgado, M C |e verfasserin |4 aut | |
700 | 1 | |a Martín-Macho González, M |e verfasserin |4 aut | |
700 | 1 | |a Martín Villén, L |e verfasserin |4 aut | |
700 | 1 | |a Nuvials Casals, X |e verfasserin |4 aut | |
700 | 1 | |a Ortiz Suñer, A |e verfasserin |4 aut | |
700 | 1 | |a Quintana Díaz, M |e verfasserin |4 aut | |
700 | 1 | |a Rascado Sedes, P |e verfasserin |4 aut | |
700 | 1 | |a Recuerda Núñez, M |e verfasserin |4 aut | |
700 | 1 | |a Del Río Carbajo, L |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez Aguirregabiria, M |e verfasserin |4 aut | |
700 | 1 | |a Rodríguez Oviedo, A |e verfasserin |4 aut | |
700 | 1 | |a Seijas Betolaza, I |e verfasserin |4 aut | |
700 | 1 | |a Soriano Cuesta, C |e verfasserin |4 aut | |
700 | 1 | |a Suberviola Cañas, B |e verfasserin |4 aut | |
700 | 1 | |a Vera Ching, C |e verfasserin |4 aut | |
700 | 1 | |a Vidal González, Á |e verfasserin |4 aut | |
700 | 1 | |a Zapata Fenor, L |e verfasserin |4 aut | |
700 | 1 | |a Zaragoza Crespo, R |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Medicina intensiva |d 2017 |g 46(2022), 2 vom: 01. Feb., Seite 81-89 |w (DE-627)NLM25948640X |x 2173-5727 |7 nnns |
773 | 1 | 8 | |g volume:46 |g year:2022 |g number:2 |g day:01 |g month:02 |g pages:81-89 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medine.2021.11.019 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 46 |j 2022 |e 2 |b 01 |c 02 |h 81-89 |